SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatm... SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.11 | -8.94308943089 | 1.23 | 1.24 | 1.06 | 272849 | 1.12373941 | CS |
4 | -0.07 | -5.88235294118 | 1.19 | 1.4 | 1.06 | 177078 | 1.20163301 | CS |
12 | -0.43 | -27.7419354839 | 1.55 | 1.62 | 1.06 | 153148 | 1.32736058 | CS |
26 | -0.88 | -44 | 2 | 2.29 | 1.06 | 145909 | 1.55416593 | CS |
52 | -0.52 | -31.7073170732 | 1.64 | 3.07 | 1.06 | 189465 | 1.78789349 | CS |
156 | -5.94 | -84.1359773371 | 7.06 | 7.58 | 1.06 | 352026 | 2.68914482 | CS |
260 | 0.3741 | 50.154176163 | 0.7459 | 11.3 | 0.5 | 435400 | 3.3663905 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales